Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 11/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340251 | 0.92 | ADRA1D (0.54) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6337709 | 0.91 | ADRA1D (0.60) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6347834 | 0.91 | ADRA1D (0.60) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6338169 | 0.90 | ADRA1D (0.56) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6340733 | 0.88 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BCACNA1FCACNA1D | |
| SCHEMBL6336410 | 0.86 | PDE1C (0.57) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6339673 | 0.85 | ADRA1D (0.56) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6337609 | 0.85 | ADRA1D (0.56) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6341555 | 0.82 | CACNA1B (0.54) | ADRA1DADRA1AADRA1BPDE1CCACNA1F | |
| SCHEMBL6341553 | 0.82 | CACNA1B (0.54) | ADRA1DADRA1AADRA1BPDE1CCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855716-B2 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO. INC (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1193259-A1 | DIHYDROPYRIMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | CACNA1B, CACNA1D, CACNA1G | ADRA1D 1250/4885ADRA1A 1601/4885ADRA1B 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.